# PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

> **NCT00829829** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Intercritical Gout

## Interventions

- **OTHER:** Placebo
- **DRUG:** Rilonacept 80 mg
- **DRUG:** Rilonacept 160 mg

## Key facts

- **NCT ID:** NCT00829829
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829829, "PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00829829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*